randomly assigned 55 patients with biopsy-confirmed NASH and either impaired glucose tolerance or type 2 diabetes to receive a hypocaloric diet plus either pioglitazone (30 mg daily for 2 months ...

Participants were randomly allocated to 16 weeks of either active (pioglitazone 30 mg daily) or placebo treatment. One woman in each group withdrew (one pregnancy and one adverse reaction to ...

Texas researchers randomized 602 patients with impaired glucose tolerance to placebo or pioglitazone (starting dose of 30 mg, titrated to a target of 45 mg daily). Mean follow-up in this industry ...